Halozyme Therapeutics (NASDAQ:HALO) Posts Earnings Results, Misses Estimates By $0.05 EPS
Halozyme Therapeutics (NASDAQ:HALO) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.05), Briefing.com reports. Halozyme Therapeutics had a negative return on equity of 16.97% and a negative net margin of 23.53%. The firm had revenue of $46.20 million for the quarter, compared to analyst estimates of $54.96 million. During the same period last year, the business earned ($0.19) earnings per share. The firm’s quarterly revenue was up 80.5% compared to the same quarter last year.
NASDAQ HALO traded up $0.63 during trading on Thursday, reaching $18.30. 32,464 shares of the company traded hands, compared to its average volume of 1,480,984. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.57 and a current ratio of 2.89. The stock’s 50 day moving average price is $15.75 and its two-hundred day moving average price is $16.15. The company has a market cap of $2.43 billion, a price-to-earnings ratio of -31.55 and a beta of 1.78. Halozyme Therapeutics has a 1-year low of $13.24 and a 1-year high of $18.03.
A number of research firms recently weighed in on HALO. Barclays raised Halozyme Therapeutics from an “underweight” rating to an “equal weight” rating and decreased their target price for the stock from $17.00 to $16.00 in a research report on Tuesday, November 5th. ValuEngine downgraded Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, October 21st. BMO Capital Markets lifted their target price on Halozyme Therapeutics from $16.00 to $17.00 and gave the stock a “market perform” rating in a research report on Wednesday. Zacks Investment Research raised Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating and set a $18.00 target price on the stock in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. lifted their target price on Halozyme Therapeutics from $20.00 to $23.00 and gave the stock an “overweight” rating in a research report on Wednesday. Four analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. Halozyme Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $20.33.
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Recommended Story: The benefits and drawbacks of dollar cost averaging
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.